The effect of a 13-valent conjugate pneumococcal vaccine on circulating antibodies against oxidized LDL and phosphorylcholine in man: a randomized placebo-controlled clinical trial

Grievink, H.W.; Gal, P.; Ozsvar Kozma, M.; Klaassen, E.S.; Kuiper, J.; Burggraaf, J.; Binder, C.J.; Moerland, M.

doi:doi:10.3390/biology9110345

Grievink, H.W.; Gal, P.; Ozsvar Kozma, M.; Klaassen, E.S.; Kuiper, J.; Burggraaf, J.; ... ; Moerland, M. (2020)

The effect of a 13-valent conjugate pneumococcal vaccine on circulating antibodies against oxidized LDL and phosphorylcholine in man: a randomized placebo-controlled clinical trial

using the Prevenar-13 vaccine. Twenty-four healthy male volunteers were vaccinated with Prevenar-13, either three times, twice or once in a double-blind, placebo-controlled, randomized single center clinical study. Anti-pneumococcal wall, oxLDL and phosphorycholine antibody levels were measured at a fixed serum dilution, as well as circulating lipid levels over the course of 68 weeks. A significant increase in anti-oxLDL IgG and IgM was seen in the group receiving two doses six months apart compared to the placebo. However, these differences were not observed in the groups receiving a single dose, two doses one month apart, or three doses. This study shows that vaccination with Prevenar-13 does not result in robust anti-oxLDL IgM levels in humans. Further research would be required to test alternative pneumococcal-based vaccines, vaccination regimens or study populations, such as cardiovascular disease patients.

Cardiovascular disease

Vaccine

Clinical trials

Translational medicine

Atherosclerosis

oxLDL

Phosphorylcholine